|1.||Body Dysmorphic Disorders (Body Dysmorphic Disorder)
|2.||Somatoform Disorders (Somatoform Disorder)
|4.||Tic Disorders (Tic Disorder)
|5.||Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)
|1.||Fallon, Brian A: 5 articles (06/2011 - 07/2003)|
|2.||Greeven, Anja: 3 articles (05/2014 - 01/2007)|
|3.||van Balkom, Anton J L M: 3 articles (05/2014 - 01/2007)|
|4.||Spinhoven, Philip: 3 articles (05/2014 - 01/2007)|
|5.||Witthöft, Michael: 2 articles (03/2016 - 11/2008)|
|6.||Zitman, Frans G: 2 articles (08/2014 - 01/2007)|
|7.||Sirri, Laura: 2 articles (03/2013 - 01/2008)|
|8.||Fava, Giovanni A: 2 articles (03/2013 - 01/2008)|
|9.||Fava, Maurizio: 2 articles (07/2011 - 01/2007)|
|10.||Barsky, Arthur J: 2 articles (01/2011 - 01/2010)|
|1.||7,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)IBA
08/01/2014 - "We aimed to generate reference values for a healthy population and for a population of patients fulfilling diagnostic criteria for at least one of BDD, hypochondriasis, and CFS, treated in specialized mental health care. "
06/01/2010 - "This article provides a focused review of issues pertaining to BDD that are relevant to DSM-V. The review presents a number of options and preliminary recommendations to be considered for DSM-V: (1) Criterion A may benefit from some rewording, without changing its focus or meaning; (2) There are both advantages and disadvantages to adding a new criterion to reflect compulsive BDD behaviors; this possible addition requires further consideration; (3) A clinical significance criterion seems necessary for BDD to differentiate it from normal appearance concerns; (4) BDD and eating disorders have some overlapping features and need to be differentiated; some minor changes to DSM-IV's criterion C are suggested; (5) BDD should not be broadened to include body integrity identity disorder (apotemnophilia) or olfactory reference syndrome; (6) There is no compelling evidence for including diagnostic features or subtypes that are specific to gender-related, age-related, or cultural manifestations of BDD; (7) Adding muscle dysmorphia as a specifier may have clinical utility; and (8) The ICD-10 criteria for hypochondriacal disorder are not suitable for BDD, and there is no empirical evidence that BDD and hypochondriasis are the same disorder. "
01/01/2006 - "Current practice in DSM-IV is to classify OCD, BDD or hypochondriasis and a delusional disorder as separate entities; this way of classifying seems to be an artefact. "
01/01/2006 - "For instance, OCD, hypochondriasis, BDD and to a lesser degree anorexia nervosa can all be particularized as 'with good insight', 'with poor insight' or 'with psychotic features'. "
06/01/1995 - "Future research may indicate that obsessional disorders such as BDD, anorexia, OCD, and hypochondriasis, as well as other disorders such as major depression, should have qualifiers or subtypes--for example, "with good insight," "with poor insight," and "with delusional (or psychotic) thinking"--with an implied continuum of insight embraced by a single disorder. "
|2.||Paroxetine (Paxil)FDA LinkGeneric
05/01/2014 - "The follow-up was at most 6 years and was performed within the scope of a randomized controlled trial that investigated the efficacy of cognitive behavioral therapy, paroxetine, and placebo in hypochondriasis. "
01/01/2007 - "This study, to the authors' knowledge, is the first randomized controlled trial comparing the efficacy of cognitive behavior therapy (CBT), paroxetine, and a placebo (administered in a double blind fashion) in the treatment of hypochondriasis. "
07/01/2001 - "5. The results of this study suggest that patients with hypochondriasis may be responsive to paroxetine. "
07/01/2001 - "2. This open study evaluates the efficacy and tolerance of paroxetine in 11 patients with DSM-III-R hypochondriasis. "
07/01/2001 - "An open study of paroxetine in hypochondriasis."
|3.||Antidepressive Agents (Antidepressants)IBA
|4.||Fluoxetine (Prozac)FDA LinkGeneric
12/01/2008 - "More patients responded with improvement in hypochondriasis when given fluoxetine compared with placebo, starting at week 8 (50.0% vs 19.0%, P = 0.03) and continuing to week 12 (62.5% vs 33.3%, P = 0.05). "
12/01/2008 - "Fluoxetine is a moderately effective and well-tolerated treatment for hypochondriasis."
12/01/2008 - "This study assessed the efficacy, durability, and tolerability of fluoxetine for hypochondriasis, a disorder for which controlled pharmacological trials are scarce. "
12/01/2008 - "A double-masked, placebo-controlled study of fluoxetine for hypochondriasis."
01/01/1996 - "Preliminary results from an ongoing placebo-controlled trial of hypochondriasis using fluoxetine are presented. "
|5.||Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
01/01/1996 - "We review the case reports and small uncontrolled series on the pharmacologic treatment of hypochondriasis, emphasizing the growing body of evidence suggesting particular efficacy for the serotonin reuptake inhibitors. "
07/01/2011 - "When both study samples were pooled, we found associations for anxiety (psychic; selective serotonin reuptake inhibitors arm), somatic (gastrointestinal), and hypochondriasis (Hypericum arm), and anxiety (psychic) and somatic (general) symptoms (placebo arm). "
05/01/2009 - "Serotonin reuptake inhibitors (SRIs) have shown benefits as first-line, short-term treatments for body dysmorphic disorder, hypochondriasis, onychophagia, and psychogenic excoriation, with some benefits in trichotillomania, pathological gambling, and compulsive buying. "
04/01/2004 - "The review reveals that patients with the obsessional cluster of somatoform disorders (hypochondriasis and body dysmorphic disorder [BDD]) respond well to serotonin reuptake inhibitors (SRIs). "
|6.||nefazodone (Serzone)FDA LinkGeneric
07/01/2002 - "The results of this study suggest that nefazodone is a promising treatment for hypochondriasis. "
07/01/2002 - "Eleven patients with a primary diagnosis of DSM-IV hypochondriasis received an 8-week trial of nefazodone with a maximum dose of 600 mg/day and a mean dose of 432 mg. Clinician and self-ratings were completed at each of six visits. "
07/01/2002 - "The purpose of the present study was to evaluate the use of nefazodone in the treatment of hypochondriasis in an open-label trial. "
07/01/2002 - "An open-label clinical trial of nefazodone in hypochondriasis."
11/01/2008 - "The presence of hypochondriasis increased greatly the risk for co-morbid disorders. "
05/01/2001 - "Hypochondriasis is recognized as an important disorder in clinical populations, associated with increased health care utilization, disability and psychiatric co-morbidity. "
03/01/1997 - "In contrast, presence of co-existing OC Related Syndrome was significantly linked to higher impulsivity score, especially with "Intermittent Explosive Syndrome" (mean score = 40.1 vs 30.8, p < 10(-4), "Compulsive Buying" (38.5 vs 32.4, p = 0.005), "Hypochondriasis" (36.7 vs 32.1, p = 0.02), "Dysmorphophobia" (37.1 vs 32.4, p = 0.02) and "Depersonnalization" (37.7 vs 32.9, p = 0.05). "
09/01/1997 - "Patients with this abridged hypochondriasis were more likely than those without to have co-morbid major depression and generalized anxiety disorder. "
11/01/1994 - "While hypochondriasis and panic disorder co-occur to some extent in a primary care population, the overlap is by no means complete. "
|8.||duloxetine (Cymbalta)FDA Link
01/01/2007 - "Compared to SSRI-treated patients, duloxetine-treated patients had a significantly greater (p < or = 0.05) reduction in the 17-item Hamilton Depression Rating Scale (HAMD17) total score and HAMD17 items of work and activities, psychomotor retardation, genital symptoms and hypochondriasis. "
06/30/2007 - "Successful treatment of refractory hypochondriasis with duloxetine."
12/01/2001 - "After treatment, the average values of MMPI on falseness (F), hypochondriasis (HS), depression (D) and psychosthenia (Pt) in the treated group were all improved (P < 0.01 or P < 0.05); but in the control group, significant difference only showed in MMPI on HS (P < 0.05). "
07/01/1997 - "The results were analysed up to 6 months after treatment and showed the treated patients to be moderately but significantly improved with respect to physical illness and somatic preoccupation, hypochondriasis, and medication usage. "
03/01/2016 - "Changes in negative implicit evaluations in patients of hypochondriasis after treatment with cognitive therapy or exposure therapy."
01/01/2011 - "Scores on the 3 measures of hypochondriasis were significantly decreased after treatment in the CBT compared with the control group. "
01/01/2008 - "They showed a high test-retest reliability in normal subjects, and changed in the expected direction after treatment of hypochondriasis. "
01/01/1991 - "The Illness Attitude Scales have been used in a number of studies concerned with patients suffering from DSM-III-R hypochondriasis, panic disorder, melancholia, in the medically ill, in pregnant women, during medical procedures such as mammography, and in experiments in therapeutics, such as drug trials. "
05/01/2009 - "The present study aims to determine whether cognitive-behavioural minimal contact bibliotherapy is acceptable to participants suffering from DSM-IV-TR hypochondriasis, and whether this intervention is able to reduce hypochondriacal complaints, as well as comorbid depressive complaints and trait anxiety. "
05/01/2009 - "Cognitive-behavioural bibliotherapy for hypochondriasis: a pilot study."
|4.||Drug Therapy (Chemotherapy)
01/01/2000 - "To examine whether somatoform symptoms, specifically symptoms of conversion, somatization, and hypochondriasis, are associated with side-effect reporting and treatment nonadherence in depressed family medicine outpatients, and to measure whether symptoms improve with pharmacotherapy. "
01/01/1996 - "The pharmacotherapy of hypochondriasis."
12/01/1993 - "Hypochondriasis without concomitant depression is often considered to be unresponsive to pharmacotherapy. "
01/01/1987 - "The discriminant analysis confirmed that between the clinical groups the mastectomised patients exhibited higher scores (compared to those receiving chemotherapy) along the scales Hypochondriasis, Paranoia, Psychaesthenia, Schizophrenia and Hypomania, the latter 4 scales constituting the psychotic tetrad."
02/01/2011 - "Other disorders in the category include: somatization disorder, undifferentiated somatoform disorder, conversion disorder, hypochondriasis and body dysmorphic disorder Treatment is applied through a combination of pharmacotherapy and psychotherapy. "
01/01/2005 - "There was a statistically significant difference in age (P < 0.001), primary esophageal peristalsis on manometry (P = 0.037) and two illness behavior category scores related to hypochondriasis (P = 0.041 and P = 0.025) between laparoscopic anterior partial fundoplication and Nissen total fundoplication groups. "